(1) Durante, C. et al. (2023). 2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management. European thyroid journal, 12(5), e230067. https://doi.org/10.1530/ETJ-23-0067
(2) Haugen, B. R. et al. (2016). 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid : official journal of the American Thyroid Association, 26(1), 1–133. https://doi.org/10.1089/thy.2015.0020
(3) González, H. E. et al. (2017). A 10-Gene Classifier for Indeterminate Thyroid Nodules: Development and Multicenter Accuracy Study. Thyroid : official journal of the American Thyroid Association, 27(8), 1058–1067. https://doi.org/10.1089/thy.2017.0067
(4) Zafereo, M. et al. (2020). A Thyroid Genetic Classifier Correctly Predicts Benign Nodules with Indeterminate Cytology: Two Independent, Multicenter, Prospective Validation Trials. Thyroid : official journal of the American Thyroid Association, 30(5), 704–712. https://doi.org/10.1089/thy.2019.0490
(5) Olmos, R. et al. (2023). ThyroidPrint®: clinical utility for indeterminate thyroid cytology. Endocrine-related cancer, 30(11), e220409. https://doi.org/10.1530/ERC-22-0409
(6) Carolos, Z. et al. (2024). Uso de firmas moleculares como apoyo al diagnóstico de los nódulos tiroideos con citología indeterminada. Valor de ThyroidPrint®. https://www.seen.es/documentos/tiroseen-thyroidprint
(7) González H. et al. (2024). New sample-to-result Idylla™ ThyroidPrint® Assay accurately identifies benign thyroid nodules with indeterminate cytology: A multicenter-prospective double-blinded clinical validation trial. 46th Annual meeting of the European Thyroid Association. ETA 2024.